8-K: Windtree Therapeutics Secures $250,000 in Senior Secured Notes, Enters License and Supply Agreement with Evofem Biosciences

Windtree Therapeutics issues senior secured notes for $250,000 and partners with Evofem Biosciences to supply Phexxi outside the US.

Summary

• Windtree Therapeutics has entered into a License and Supply Agreement with Evofem Biosciences to supply Evofem's Phexxi product outside of the United States.
• The agreement has an initial three-year term with automatic two-year renewals, subject to termination provisions.
• Windtree's supply obligations will begin after Evofem's current supplier exclusivity ends or within 90 days of Windtree establishing manufacturing capabilities.
• Windtree can subcontract its obligations without Evofem's consent.
• Evofem is obligated to purchase the products from Windtree at a specified price during the first three years.
• Windtree receives a limited, nonexclusive, royalty-free license to use Evofem's intellectual property to manufacture the products for Evofem.
• On March 18, 2025, Windtree agreed to issue $250,000 in senior secured notes due in 2026 to institutional investors in a private offering.
• The notes include a 20% original issue discount.
• The notes mature on March 18, 2026, with potential extensions at the holder's option.
• The interest rate is 10% per annum, compounding monthly, increasing to 18% upon an Event of Default.
• The notes prohibit certain fundamental transactions unless obligations are assumed by the successor.
• Windtree can redeem the notes at 120% of the outstanding amount.
• If Windtree sells common stock through an equity line of credit, a portion of the notes must be redeemed using 30% of the proceeds, calculated at $1.20 per $1.00 of the outstanding amount.
• The notes are secured by first-priority security interests in all of Windtree's assets.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company secured financing and a supply agreement, the terms of the financing are somewhat unfavorable, and the company faces ongoing compliance scrutiny from Nasdaq.

Positives

• The License and Supply Agreement with Evofem Biosciences provides a potential revenue stream for Windtree Therapeutics.
• The agreement allows Windtree to subcontract manufacturing, providing flexibility.
• Windtree regained compliance with Nasdaq listing rules.

Negatives

• The senior secured notes include a 20% original issue discount, reducing the net proceeds received by Windtree.
• The notes have restrictive covenants that could limit Windtree's operational flexibility.
• The high interest rate of 18% upon an Event of Default could strain Windtree's finances.
• The Equity Line Mandatory Redemption provision could force Windtree to use equity line proceeds to redeem notes instead of for other strategic purposes.

Risks

• Windtree's ability to fulfill its supply obligations to Evofem depends on establishing manufacturing capabilities.
• The success of the Evofem partnership depends on Evofem's ability to market and sell Phexxi outside the US.
• Windtree's ability to repay the senior secured notes depends on its financial performance and ability to generate cash flow.
• Failure to comply with the covenants in the notes could trigger an Event of Default and accelerate repayment.
• The Discretionary Panel Monitor imposed by Nasdaq until March 20, 2026, indicates ongoing scrutiny of Windtree's compliance.

Future Outlook

Windtree aims to generate revenue through the Evofem partnership and advance its clinical development programs. The company's ability to execute its plans depends on securing additional capital and managing costs effectively.

Industry Context

The agreement with Evofem Biosciences reflects a trend of pharmaceutical companies outsourcing manufacturing and supply chain operations. The financing through senior secured notes is a common method for small-cap biotech companies to raise capital, although it can be more expensive than equity financing.

Comparison to Industry Standards

• The 20% original issue discount on the senior secured notes is relatively high, suggesting that Windtree may have had limited financing options.
• The 10% interest rate on the notes is also higher than typical corporate debt, reflecting the higher risk associated with investing in a small-cap biotech company.
• Comparable companies such as Aytu BioScience and Adamis Pharmaceuticals have also used secured debt financing, but their terms may vary depending on their financial condition and growth prospects.
• The License and Supply Agreement with Evofem is similar to other contract manufacturing agreements in the pharmaceutical industry, where companies specialize in manufacturing and supply chain services for other firms.

Related Party Transactions

• Saundra Pelletier, the President and Chief Executive Officer of Evofem, is also a member of Windtree's board of directors, creating a potential conflict of interest.

Stakeholder Impact

• Shareholders may be impacted by the dilution from potential equity issuances related to the equity line of credit.
• Employees may be affected by the company's ability to execute its business plan and maintain financial stability.
• Customers of Evofem Biosciences may benefit from a more reliable supply of Phexxi outside the US.
• Creditors are impacted by the issuance of senior secured notes and the security interest in Windtree's assets.

Next Steps

• Windtree needs to establish manufacturing capabilities for Phexxi to fulfill its obligations under the License and Supply Agreement.
• Windtree must manage its finances to comply with the covenants in the senior secured notes and avoid an Event of Default.
• Windtree needs to continue to meet Nasdaq listing requirements to avoid delisting.

Key Dates

Keywords

Senior Secured Notes, License Agreement, Evofem Biosciences, Phexxi, Windtree Therapeutics, Redemption, Nasdaq, Financing, Debt